Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

Fig. 1

(A) Kaplan-Meier estimates of progression-free survival in all patients. (B) Subgroup analysis of progression-free survival. (C) Kaplan-Meier estimates of progression-free survival in patients treated with first-line 1st /2nd and 3rd generation EGFR-TKIs. (D) Kaplan-Meier estimates of progression-free survival in patients with and without brain metastases. Tick marks indicate censored data. CI, confidence interval; HR, hazard ratio; mPFS, median PFS

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us